Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365802 · ClinicalTrials.gov registry record · Early Phase 1
FAPI PET for Lung Fibrosis
A Early Phase 1 study of Interstitial Lung Disease and Pulmonary Fibrosis, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05365802 is a Early Phase 1 study of Interstitial Lung Disease and Pulmonary Fibrosis that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05365802, a Early Phase 1 study of Interstitial Lung Disease and Pulmonary Fibrosis, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan and one High Resolution CT of the lungs. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG 68Ga-FAPi-46
- PROCEDURE High Resolution Computed Tomography
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05365802
The ClinicalTrials.gov registry entry for NCT05365802 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (95% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT05365802 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05365802 about?
NCT05365802 is a clinical study titled "FAPI PET for Lung Fibrosis". This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung di...
What is the current status of trial NCT05365802?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2021-11-16. Estimated completion is 2026-12.
What conditions does trial NCT05365802 study?
This clinical trial studies the following conditions: Interstitial Lung Disease, Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis.
What interventions are being tested in trial NCT05365802?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), 68Ga-FAPi-46 (DRUG), High Resolution Computed Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT05365802?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05365802 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RECRUITING · Phase 3
-
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
RECRUITING
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.